Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

HER2-positive circulating tumor cells in breast cancer.

Auteurs : Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : PLoS One
Volume : 6(1)
Pagina's : e15624

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Auteurs : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pagina's : 721-30

DNA methylation profiling reveals a predominant immune component in breast cancers.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Jaar : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pagina's : 726-41

Multifactorial approach to predicting resistance to anthracyclines.

Auteurs : Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L
Jaar : 2011
Journal : J. Clin. Oncol.
Volume : 29(12)
Pagina's : 1578-86